StockNews.com began coverage on shares of Aeterna Zentaris (NASDAQ:AEZS – Get Free Report) (TSE:AEZ) in a note issued to investors on Friday. The firm set a “sell” rating on the biopharmaceutical company’s stock.
Aeterna Zentaris Price Performance
NASDAQ:AEZS opened at $3.35 on Friday. Aeterna Zentaris has a one year low of $3.96 and a one year high of $12.00. The firm has a 50-day moving average of $3.87 and a 200-day moving average of $5.61. The company has a market cap of $6.01 million, a PE ratio of -0.23 and a beta of 1.55.
Aeterna Zentaris Company Profile
See Also
- Five stocks we like better than Aeterna Zentaris
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Airbnb Stock Attracts Attention With Strong Cash Flow Strategy
- Conference Calls and Individual Investors
- MarketBeat Week in Review – 11/4 – 11/8
- Do Real Estate Investment Trusts Deserve a Place in Your Portfolio?
- Trump’s Return: Which Sectors Will Benefit Most?
Receive News & Ratings for Aeterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aeterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.